See the DrugPatentWatch profile for pediatric
The U.S. Food and Drug Administration (FDA) designates pediatric exclusivity for drugs that meet specific criteria, typically requiring new clinical investigations in the pediatric population. Information on specific grants for 2024 would be detailed in FDA communications and published lists.
What is Pediatric Exclusivity?
Pediatric exclusivity is a period of market exclusivity granted to the sponsor of a drug in exchange for conducting studies in the pediatric population. This incentive encourages the development of drugs for children, ensuring that they have safe and effective treatments tailored to their needs. The exclusivity is typically six months and is added to any existing patent or exclusivity periods [1].
How Does a Drug Qualify for Pediatric Exclusivity?
To qualify for pediatric exclusivity, a drug sponsor must submit a written request to the FDA before the drug's approval. The FDA then issues a Written Request specifying the pediatric studies that may be conducted. If the sponsor completes these studies in accordance with the Written Request and they are approved by the FDA, the drug is granted six months of pediatric exclusivity. This exclusivity can be granted to any approved drug product, including generics, if the conditions are met [1].
When Does Pediatric Exclusivity Typically Apply?
Pediatric exclusivity is granted when new clinical investigations of the drug are conducted in children. These studies can involve a variety of research, such as testing new indications, new formulations, or new dosages for pediatric use. The goal is to gather essential data on the drug's safety and efficacy in children, as their physiology can differ significantly from adults [1].
What is the Duration of Pediatric Exclusivity?
The standard period for pediatric exclusivity is six months. This exclusivity is appended to any existing patent or other exclusivity periods that the drug may already have. This means that the six-month extension begins after the expiration of any prior exclusivity or patent protection.
How Can I Find a List of FDA Pediatric Exclusivity Grants for 2024?
Information regarding FDA pediatric exclusivity grants for 2024 would be officially published by the FDA. Such announcements are typically found on the FDA's official website, often within sections dedicated to drug approvals, pediatric information, or patent and exclusivity data. Resources like DrugPatentWatch.com may also track and list such designations as they become publicly available [2].
What are the Implications of Pediatric Exclusivity for Drug Development?
Pediatric exclusivity serves as a critical incentive for pharmaceutical companies to invest in pediatric drug research. Without this incentive, the development of drugs for children may be less commercially attractive due to the costs and complexities of pediatric trials. The granting of exclusivity helps ensure that children have access to a wider range of scientifically validated treatments.
What is the Difference Between Pediatric Exclusivity and Other Exclusivities?
Pediatric exclusivity is distinct from other forms of market exclusivity, such as New Chemical Entity (NCE) exclusivity or orphan drug exclusivity. NCE exclusivity is typically five years for a new molecular entity. Orphan drug exclusivity is seven years for drugs treating rare diseases. Pediatric exclusivity is a six-month add-on granted specifically for the completion of pediatric studies, irrespective of the drug's other exclusivity or patent statuses.
*
**Sources:
[1] https://www.fda.gov/about-fda/pediatric-drug-development/pediatric-exclusivity
[2] https://drugpatentwatch.com/